en · de · es · pt
cjc-1295-notes.peptides3081.com › Info › Handling, Stability And Analysis — Deep Dive

Handling, Stability And Analysis — Deep Dive

By Editorial Desk · published 2026-03-26 · last reviewed 2026-05-15 · Info

RP-HPLC is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.

Updated 2026-05-15. Numbers and descriptions here follow the published literature rather than marketing material.

Handling, Stability and Analysis

Identity and purity are assessed mainly by reversed-phase high-performance liquid chromatography combined with mass spectrometry. The chromatographic separation resolves the target peptide from truncation products and from species carrying oxidised residues, while mass measurement confirms the expected molecular mass. Because the two common variants differ by roughly 280 daltons, a mass determination distinguishes them unambiguously. Purity is often quoted as a percentage of total peak area, although that figure depends on the detection wavelength and the integration method applied.

Reported half-lives differ widely between the two variants and between species. Values for the albumin-binding form are usually expressed in days, while the unconjugated form is measured in minutes to a few hours. Sampling schedules, assay sensitivity, and route of administration all influence the numbers, which limits direct comparison across studies. Whether sustained receptor occupancy produces different downstream effects from pulsatile stimulation remains an open question in the published work. Claims about relative potency should therefore be read alongside the specific study design that produced them.

Background and Naming Conventions

CJC-1295 is a synthetic peptide analog of growth hormone-releasing hormone, constructed on the 29-amino-acid fragment designated GRF(1-29). The name began as an internal development code during the 1990s and later spread through research supply catalogs and discussion forums. The molecule does not occur in nature; its sequence is engineered rather than isolated from tissue. Two related compounds are sold under this single label, and they differ by one appended chemical group that strongly influences how long the peptide remains in circulation.

The dividing feature between the two forms is a maleimide-based drug affinity complex, abbreviated DAC. In the DAC-bearing version, a linker attaches the peptide to serum albumin after administration, and that association slows removal from plasma. The version lacking DAC appears in catalogs as MOD GRF(1-29) or tetrasubstituted GRF(1-29). Because informal writing treats both as one item, comparisons drawn from such sources routinely blend measurements taken from two molecules with substantially different behavior.

Cjc-1295 at a glance

PropertyValueNotes
Appearance as powderWhite to off-white solidMinor batch-to-batch variation is normal
Solubility classSoluble in water and aqueous buffersDissolution can be slowed by aggregates
Typical storage temperatureMinus 20 degrees Celsius or belowProtected from light and moisture
Storage after reconstitution2 to 8 degrees Celsius, short termLonger holding requires freezing
Common analytical methodReversed-phase HPLC with mass spectrometryUsed for purity and identity confirmation

Structure And Receptor Pharmacology

CJC-1295 belongs to a class of synthetic peptides modeled on growth hormone releasing hormone, a forty-four amino acid signal produced by the hypothalamus. The compound is built from the first twenty-nine residues of the natural sequence, with four substitutions introduced at positions 2, 8, 15 and 27. These changes were designed to slow enzymatic breakdown while preserving receptor activation. The result is a peptide that is shorter than native GHRH and considerably more resistant to ordinary clearance pathways in circulation.

Two related forms appear under the CJC-1295 name. The simpler analogue, commonly written as modified GRF(1-29), carries the four substitutions but no additional conjugation. The second form attaches a maleimidopropionic acid linker to a lysine residue, a modification frequently called the drug affinity complex. That linker reacts with the free thiol on serum albumin to form a covalent bond. Because albumin has a long residence time in blood, the conjugated peptide stays in circulation far longer than the unconjugated analogue.

Receptor level activity follows the canonical GHRH pathway. The peptide binds the GHRH receptor, a class B G protein coupled receptor on somatotroph cells of the anterior pituitary. Binding raises intracellular cyclic AMP, which promotes calcium entry and the release of growth hormone into the bloodstream. Because the molecule acts at the same receptor as the endogenous hormone, its effect is superimposed on the natural pulsatile rhythm rather than replacing it. Whether sustained receptor occupation leads to desensitization is not fully settled.

Related pages on this site

CJC-1295 Background and Mechanism

The peptide binds GHRH receptors on somatotroph cells within the anterior pituitary, triggering a signalling cascade that increases growth hormone secretion. Its improved resistance to dipeptidyl peptidase IV degradation distinguishes it from the parent hormone. In the DAC-bearing version, a maleimide group reacts with a cysteine residue on serum albumin, forming a covalent bond that keeps the peptide in circulation far longer. That albumin attachment is the central design feature separating the two research variants.

Pharmacokinetic behaviour differs sharply between the two forms. The DAC-bearing peptide shows an extended circulation time measured in days, whereas the version without the complex is cleared within roughly half an hour. This gap shapes how researchers design dosing schedules in animal models. Whether the prolonged presence of the DAC form produces effects meaningfully different from the short-acting variant remains an open question, since comparative human data are scarce.

Supporting material

=== Nanotechnology === Operando spectroscopy has become a vital tool for surface chemistry. Nanotechnology, used in materials science, involves active catalytic sites on a reagent surface with at least one dimension in the nano-scale of approximately 1–100 nm. As particle size decreases, surface area increases. This results in a more reactive catalytic surface. The reduced scale of these reactions affords several opportunities while presenting unique challenges; for example, due to the very small size of the crystals (sometimes <5 nm), any X-ray crystallography diffraction signal may be very weak. As catalysis is a surface process, one particular challenge in catalytic studies is resolving the typically weak spectroscopic signal of the catalytically active surface against that of the inactive bulk structure. Moving from the micro to the nano scale increases the surface to volume ratio of the particles, maximizing the signal of the surface relative to that of the bulk. Furthermore, as the scale of the reaction decreases towards nano scale, individual processes can be discerned that would otherwise be lost in the average signal of a bulk reaction composed of multiple coincident steps and species such as spectators, intermediates, and reactive sites.

== Scope of Services == Girteka specializes in temperature-controlled and high-value cargo transportation across the continent, delivering a wide range of goods, including fresh, chilled, frozen, and processed foods. Focusing on the following operational segments within road transportation:

Similarly, the compressive strength that describes the yield stress before plastic deformation under compression in graphene aerogels follows a power-law distribution: σy/Es = (ρ/ρs)n, where σy is the compressive strength, ρ is the density of the graphene aerogel, Es is the modulus of graphene, ρs is the density of graphene, and n is the power-law scaling factor that describes the system different from the exponent observed in the modulus. The power-law dependence observed agrees with trends between density and modulus and compressive strength observed in experimental studies on graphene aerogels. The macroscopic geometric structure of the aerogel has been shown both computationally and experimentally to affect mechanical properties observed. 3D-printed periodic hexagonal graphene aerogel structures exhibited an order-of-magnitude larger modulus compared to bulk graphene aerogels of the same density when the force is applied along the vertical axis. The dependence of stiffness on structure is commonly observed in other cellular structures.

Sources: en.wikipedia.org

Supporting material

In the USA and other countries it was discontinued gradually after the introduction of the electroconvulsive therapy during the 1940s and the first neuroleptic drugs during the 1950s. Dr. Sakel died from heart failure on December 2, 1957, in New York City, NY, USA.

38 Mod 3): Nimitz-class aircraft carrier, Arleigh Burke-class destroyer, Ticonderoga-class cruiser, Oliver Hazard Perry-class frigate, Wasp-class amphibious assault ship, Tarawa-class amphibious assault ship, Whidbey Island-class dock landing ship, Harpers Ferry-class dock landing ship, Austin-class amphibious transport dock, Blue Ridge-class command ship, Cyclone-class patrol ship, Mark VI patrol boat Marine Corps: LAV-25 Coast Guard (Mk. 38 Mod 0, Mk. 38 Mod 2 and Mk. 38 Mod 3): Reliance-class cutter, Hamilton-class cutter, Sentinel-class cutter, Island-class cutter, USCGC Alex Haley, future Heritage-class cutter

The plantar fascia is the thick central portion of the fascia investing the plantar muscles. It extends between the medial process of the tuber calcanei and the proximal phalanges of the toes. It provides some attachment to the flexor muscles of the toes.‍ Distally, the plantar fascia becomes continuous with the fibrous sheaths enveloping the flexor tendons passing to the toes. At the anterior extremity of the sole – inferior to the heads of the metatarsal bones – the plantar aponeurosis forms the superficial transverse metatarsal ligament.‍

Sources: en.wikipedia.org

Supporting material

Most depleted uranium arises as a by-product of the production of enriched uranium for use as fuel in nuclear reactors and in the manufacture of nuclear weapons. Enrichment processes generate uranium with a higher-than-natural concentration of lower-mass-number uranium isotopes (in particular 235U, which is the uranium isotope supporting the fission chain reaction) with the bulk of the feed ending up as depleted uranium. Natural uranium metal contains about 0.71% 235U, 99.28% 238U, and about 0.0054% 234U. The production of enriched uranium using isotope separation creates depleted uranium containing only 0.2% to 0.4% 235U. Because natural uranium begins with such a low percentage of 235U, enrichment produces large quantities of depleted uranium. For example, producing 1 kilogram (2.2 lb) of 5% enriched uranium requires 11.8 kilograms (26 lb) of natural uranium, and leaves about 10.8 kilograms (24 lb) of depleted uranium having only 0.3% 235U. Depleted uranium is further produced by recycling spent nuclear fuel, in which case it contains traces of neptunium and plutonium. These quantities are so small that they are not considered to be of serious radiological significance by the European Committee on Radiation Risk. DU from nuclear reprocessing has different isotopic ratios from enrichment-by-product DU, from which it can be distinguished by the presence of 236U. The only known natural source of uranium with a 235U content significantly different from 0.71% is found in the natural nuclear fission reactor at Oklo, Gabon.

Although canagliflozin produces beneficial effects on HDL cholesterol, it has also been shown to increase LDL cholesterol to produce no change in total cholesterol. Evidence shows that apart from positive effects on glycemic levels, canagliflozin also reduces the risk of heart attacks and heart failures. SGLT2 inhibitors, including canagliflozin, reduce the likelihood of hospitalization for congestive heart failure or progression of renal disease in persons with diabetes mellitus type 2 and reduce the likelihood of stroke and heart attack in persons with diabetes mellitus type 2 who have known atherosclerotic vascular disease.

On 15 September 2008, RIA Novosti reported that Russian foreign minister Sergey Lavrov said: "There were excesses by all parties, but this was a war, and when you see on night, that you are being fired upon and you're on the move, while you're advancing to help Tskhinvali, then your response can not be precisely accurate and cannot avoid hurting anyone." On 21 September 2008, Russia-1 TV reported that the wife of Lieutenant Sergey Shevelev, intelligence officer of the peacemaking battalion who died in South Ossetia, said that her husband called her every day and they talked casually. However, on 1 August he sent her text message saying "Everything is normal ... Watch TV. That's all." Konstantin Timerman, the commander of the Russian peacekeeping battalion, said in 2017 that as soon as his combat buddy Sergey Shevelev arrived in Tskhinvali on 1 August 2008, the escalation of the conflict began.

== History == The original Landspítali began operations on 20 December 1930. Ideas for a hospital that served the whole country was not new; in 1863, Jón Hjaltalín, the then Director of Health, proposed a bill that would establish such a hospital, but the bill was not voted on. During the period from 1863 to 1930, several hospitals operated in Reykjavík. The founding of Landspítali was the product of a long, hard struggle in which women were at the forefront and have ever since played a huge role in the country's hospital matters. In 2000, the Reykjavik City Hospital merged with Landspítali, and the new merged hospital was renamed as Landspítali University Hospital (Landspítali háskólasjúkrahús; LSH) until it reverted to its original name in 2007.

Sources: en.wikipedia.org

Frequently asked questions

Why is mass spectrometry used alongside chromatography?

Chromatography reports how much material elutes as a single peak but does not confirm what that material is. Mass spectrometry supplies the molecular mass, which is characteristic of a given sequence and its modifications. Together the two methods support both a purity figure and an identity claim.

What drives degradation of the peptide in solution?

Hydrolysis, oxidation of susceptible residues, and aggregation all contribute, and their rates depend on pH, temperature, and concentration. Dissolved oxygen and trace metal ions accelerate oxidation. Keeping solutions cold, dilute, and free of unnecessary handling reduces these pathways.

Is a purity percentage directly comparable between suppliers?

Not always, because the value depends on the detection wavelength, the gradient, and how peak areas are integrated. A figure of ninety-eight percent from one laboratory may not mean the same as the same number from another. Comparing full chromatograms and mass spectra is more informative than comparing a single number.

Does this compound occur naturally in the body?

No. It is a laboratory-synthesized analog built on a fragment of the natural hormone. The natural peptide is shorter-lived and lacks the stabilizing substitutions found in the synthetic version.

Network